We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+9.54%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$109B
AUM Growth
+$10.1B
Cap. Flow
+$2.06B
Cap. Flow %
1.89%
Top 10 Hldgs %
23.41%
Holding
4,156
New
227
Increased
1,649
Reduced
1,885
Closed
242

Sector Composition

Rank Sector Weight
1 Technology 12.51%
2 Healthcare 9.35%
3 Financials 9.21%
4 Industrials 6.82%
5 Consumer Discretionary 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MGF
3651
Aberdeen Government Markets Income Fund
MGF
$92.6M
$88.5K ﹤0.01%
26,743
+948
+4% +$3.12K
ABBV icon
3652
CALL
AbbVie
ABBV
$442B
$86.5K ﹤0.01%
37,900
+9,100
+32% +$1.4M
CMRX
3653
DELISTED
Chimerix, Inc.
CMRX
$85.7K ﹤0.01%
+46,057
New +$90.1K
INTZ
3654
DELISTED
INTRUSION INC NEW
INTZ
$85K ﹤0.01%
26,906
-26,209
-49% -$82.8K
ADTH
3655
DELISTED
AdTheorent Holding Co
ADTH
$83K ﹤0.01%
50,000
-483,612
-91% -$932K
ADAM
3656
Adamas Trust
ADAM
$919M
$81.9K ﹤0.01%
8,002
+1,352
+20% +$14.4K
PRQR icon
3657
ProQR Therapeutics
PRQR
$271M
$79.7K ﹤0.01%
21,550
-29,611
-58% -$38.8K
VBIV
3658
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$79.5K ﹤0.01%
6,779
-2,961
-30% -$52.2K
HMY icon
3659
Harmony Gold Mining
HMY
$12.2B
$77.8K ﹤0.01%
22,892
-114
-0.5% -$360
ONDS icon
3660
Ondas Inc
ONDS
$5.56B
$77.8K ﹤0.01%
48,935
-4,345
-8% -$12.8K
MSC
3661
Studio City International Holdings
MSC
$327M
$77.4K ﹤0.01%
12,986
HTZWW
3662
Hertz Global Holdings Warrants
HTZWW
$102M
$75.7K ﹤0.01%
+10,152
New +$89.5K
VRM icon
3663
Vroom Inc
VRM
$51.5M
$75.7K ﹤0.01%
927
-783
-46% -$67.2K
GANX icon
3664
Gain Therapeutics
GANX
$87.9M
$75.1K ﹤0.01%
24,000
WBA
3665
CALL
DELISTED
Walgreens Boots Alliance
WBA
$74.7K ﹤0.01%
124,200
+4,100
+3% +$154K
CIK
3666
Credit Suisse Asset Management Income Fund
CIK
$135M
$74.4K ﹤0.01%
29,530
-185,351
-86% -$482K
SCS
3667
DELISTED
Steelcase
SCS
$74.4K ﹤0.01%
10,521
-37
-0.4% -$273
CGEN icon
3668
Compugen
CGEN
$221M
$74.2K ﹤0.01%
103,625
-26,250
-20% -$22.9K
DMF
3669
DELISTED
BNY Mellon Municipal Income
DMF
$74.1K ﹤0.01%
11,844
-6,916
-37% -$42.8K
AIV
3670
Aimco
AIV
$376M
$73.9K ﹤0.01%
+10,385
New +$79.2K
PAVMZ
3671
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$73.9K ﹤0.01%
+335,936
New +$139K
OXSQ icon
3672
Oxford Square Capital
OXSQ
$155M
$72.1K ﹤0.01%
23,122
-1,972
-8% -$6.01K
AMC icon
3673
AMC Entertainment Holdings
AMC
$2.14B
$71.5K ﹤0.01%
+1,757
New +$111K
INTC icon
3674
CALL
Intel
INTC
$493B
$71K ﹤0.01%
53,000
-104,900
-66% -$2.91M
FSCO
3675
FS Credit Opportunities Corp
FSCO
$1.02B
$70.9K ﹤0.01%
+15,048
New +$73K

Similar funds

Raymond James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Raymond James & Associates held 4,156 positions worth $109B, up 10% from $98.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Raymond James & Associates's Q4 2022 filing shows 227 new, 1,649 increased, 1,885 reduced and 242 closed positions. Its largest new stake was Rentokil: 285,133 shares worth $8.78M. The largest sale was iShares Expanded Tech Sector ETF, an estimated $79.2M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q4 2022 buy was Rentokil: 285,133 shares worth $8.78M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q4 2022, an estimated $169M increase.
  • Raymond James & Associates's biggest Q4 2022 reduction was iShares Expanded Tech Sector ETF, cutting an estimated $79.2M.
  • Raymond James & Associates fully exited Change Healthcare Inc. Common Stock in Q4 2022, selling an estimated $53.3M.
  • Raymond James & Associates's ten largest holdings make up 23% of its $109B portfolio in Q4 2022.
  • Raymond James & Associates opened 227 new positions and closed 242 in Q4 2022.
  • Raymond James & Associates's portfolio value rose 10% quarter-over-quarter to $109B.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.